WebMD Medical News
Laura J. Martin, MD
Aug. 22, 2011 -- Researchers from Northwestern University are reporting a major breakthrough in understanding of the cause of amyotrophic lateral sclerosis (ALS), the fatal disease also known as Lou Gehrig’s disease.
They say their discovery proves that different forms of ALS actually have a common cause and that this could lead to better strategies to treat the disease.
Their study was reported online in the journal Nature.
In ALS, nerve cells in the brain and spinal cord that control movement stop functioning. The condition leads to paralysis, and patients eventually cannot breathe or swallow on their own.
The disease afflicts about 350,000 people a year worldwide, and about half of patients die within three years of diagnosis.
Northwestern professor of neurology Teepu Siddique, MD, and his research team have been searching for the cause and underlying mechanism of ALS for more than two decades.
He tells WebMD that a critical mutation in a protein involved in the recycling of damaged nerve cells was first identified in a family followed since 1985. Nineteen of the family members over five generations were afflicted with the condition.
Only about one in 10 ALS patients have the inherited form of the disease. Because no cause had been identified in people without a family history, researchers have not been certain that different forms of ALS were actually the same disease.
Siddique and colleagues found that in people with and without inherited ALS, the disease results from the inability of a protein system to repair the nerve cells that tell the muscles what to do.
Their research centered on the protein ubiquilin2, which is involved in recycling damaged and misformed proteins in key nerve cells.
In people with ALS, ubiquilin2 does not do this effectively, leading to an accumulation of the damaged proteins and ubiquilin2 in critical nerve cells in the spinal cord and brain.
When viewed through a microscope, the protein accumulations look like twisted balls of yarn, which is a hallmark characteristic of ALS.
The findings add to the evidence that a defect in a process known as the protein degradation pathway contributes to ALS and possibly other degenerative disorders, such as Parkinson’s disease and even Alzheimer’s, the researchers conclude.
“Abnormality in protein degradation has been suspected, but there was little direct evidence before this study,” study co-author Han-Xiang Deng, MD, notes in a written statement.
Raymond Roos, MD, the Marjorie and Robert Straus Professor of Neurological Science at the University of Chicago Medical Center, says the discovery appears to represent an important step forward in the understanding of ALS.
He adds that it remains unclear why ubiquilin2 does not function properly in some patients without a family history of ALS.
“This moves the field forward in an impressive way, but like many breakthroughs, many questions remain to be answered,” he says.
There is only one drug approved for the treatment of ALS. It is used to slow disease progression but is not a cure. ALS Association President and CEO Jane H. Gilbert says effective therapies for ALS are long overdue.
“This is very exciting research that has huge promise for the discovery of new treatments,” she tells WebMD.
Lucie Bruijn, PhD, scientific director of the ALS Association, says she is optimistic that better drugs or drug combinations will emerge to slow disease progression.
Siddique is also optimistic that his team’s discovery could lead to better treatments for ALS and other diseases of the nerves.
“This is the most hopeful I have been in 25 years of research,” he says. “Previously, we were running in many different directions, but this is where we will focus from now on.”
SOURCES:Deng, H-X. Nature, published online Aug. 21, 2011.Teepu Siddique, MD, professor of neurology, Northwestern Feinberg School of Medicine, Chicago.Raymond Roos, MD, the Marjorie and Robert Straus Professor of Neurological Science, department of neurology, University of Chicago Medical Center, Chicago.Jane H. Gilbert, president and chief executive officer, ALS Association.Lucie Bruijn, PhD, science director, ALS Association.News release,Northwestern University Feinberg School of Medicine.National Institutes of Health: "Amyotrophic Lateral Sclerosis overview."
Here are the most recent story comments.View All
© 2015 Ramar Communications |
Site Map |
Privacy Statement |
Copyright & Trademark Notice |
EEO Report |
FCC Public Files |
Closed Captioning |